PF-Atlas › Clinical Trials › NCT05828953

Anlotinib Capsules in the Treatment for IPF/PF-ILDs

Anlotinib · Phase 2

Registry ID

NCT05828953

Phase

Phase 2

Status

Active, not recruiting

Drug / intervention

Anlotinib

Sponsor

First Affiliated Hospital of Wenzhou Medical University

Start

2021-09-28

Enrollment

Locations

About this trial

This is an exploratory Phase 2 study evaluating the use of Anlotinib hydrochloride capsules for the treatment of IPF/PF-ILDs, with forced vital capacity (FVC) as the primary efficacy endpoint.

View NCT05828953 on ClinicalTrials.gov →

Explore related

All Anlotinib trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT05828953 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.